KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Receivables (2020 - 2026)

Esperion Therapeutics filings provide 6 years of Receivables readings, the most recent being $140.2 million for Q4 2025.

  • On a quarterly basis, Receivables rose 74.93% to $140.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $140.2 million, a 74.93% increase, with the full-year FY2025 number at $140.2 million, up 74.93% from a year prior.
  • Receivables hit $140.2 million in Q4 2025 for Esperion Therapeutics, up from $119.0 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $140.2 million in Q4 2025 to a low of $21.7 million in Q3 2021.
  • Median Receivables over the past 5 years was $41.7 million (2023), compared with a mean of $54.3 million.
  • Biggest five-year swings in Receivables: soared 85.13% in 2021 and later increased 12.86% in 2022.
  • Esperion Therapeutics' Receivables stood at $22.9 million in 2021, then soared by 47.07% to $33.7 million in 2022, then skyrocketed by 43.78% to $48.5 million in 2023, then soared by 65.26% to $80.1 million in 2024, then skyrocketed by 74.93% to $140.2 million in 2025.
  • The last three reported values for Receivables were $140.2 million (Q4 2025), $119.0 million (Q3 2025), and $107.7 million (Q2 2025) per Business Quant data.